On May 14, 2026, Genprex, Inc. announced positive preclinical results for its diabetes gene therapy, showing it reversed hyperglycemia in mouse models during a presentation at the ASGCT Annual Meeting on May 13, 2026, suggesting potential long-term control over Type 2 diabetes.